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  Antidepressant drugs are one of the most widely used medicines for treating 
major depressive disorders for long time periods. Oral fluid testing offers an easy and 
non-invasive sample collection. Detection of antidepressants in oral fluid is important in 
clinical and forensic settings, such as therapeutic drug monitoring and roadside testing for 
driving under influence. We developed and validated a comprehensive liquid 
chromatography tandem mass spectrometry method for 18 antidepressants (amitriptyline, 
bupropion, citalopram, clomipramine, cyclobenzaprine, desipramine, desvenlafaxine, 
doxepin, duloxetine, fluoxetine, imipramine, mirtazapine, nortriptyline, paroxetine, 
sertraline, trazodone, trimipramine, venlafaxine) in oral fluid collected by Quantisal®  
oral collection devices. 0.5 mL of Quantisal®  oral fluid (125µL of neat oral fluid) was 
submitted to solid-phase extraction. The chromatographic separation was performed 
employing a biphenyl column in gradient mode with a total run time of 5 min. The MS 
detection was achieved by multiple reaction monitoring with two transitions per 
compound. The range for linearity of all analytes was from 10-1,000 ng/mL, with a limit 
of quantitation of 10 ng/mL. Results of intra and inter-day’s accuracy and precision 
(n=15) were all within acceptable limits, ± 20% error and ± 15% relative standard 
deviation. Analyte recovery at 400 ng/mL concentration (n=15) ranged from 91-129%. 
Matrix effect ranged from 73.7-157%. The internal proficiency test detected all 
antidepressants with accuracy ranging from 83.1-112.1%. The authentic patient samples 
showed percentage difference compare to the previously calculated concentration of 
86.3-111%. This method provides for the rapid detection of 18 antidepressants in oral 







Antidepressant drugs are one of the most widely used medicines that have been 
administered to treat major depressive disorders for long periods of time (NHS, 2016). 
Certain antidepressant drugs have also been used to treat anxiety and bipolar disorders in 
certain cases. In the United States, one in eight Americans aged 12 or more reported 
taking antidepressants between the year of 2011 to 2014 (Brody, Gu & Pratt 2017).  This 
number of antidepressant users increased from 7.7 to 12.7% of the adult population over 
the 15-year time frame from 1999-2014 (Brody, Gu & Pratt 2017). There are different 
types of antidepressant such as norepinephrine and dopamine reuptake inhibitors 
(NDRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin 
reuptake inhibitors (SSRIs), tricyclic antidepressants (TCA), and non-selective serotonin 
and norepinephrine reuptake inhibitors. Most of them work to regulate neurotransmitters 
such as norepinephrine or serotonin cycle in one’s brain (Coulter et al. 2010).  
  Antidepressants, especially TCA, have a narrow therapeutic window, so there lies 
a greater risk of cardiotoxicity and central nervous system (CNS) toxicity and potentially 
lethal in overdose (Castro, et al, 2008), including risk of respiratory depression (Kerr, 
McGuffie, & Wilkie 2001). SSRIs are commonly prescribed among others because of 
their low risk, fewer side effects, and better long-term outcomes (Binns, Egger, & Reznik 
2017). Because of these reasons, there is a decrease in the prescription of TCA and rise in 
SSRIs and SNRIs use (Ciraulo, Greenblatt, & Shader 2010). The growing trend for the 
use of SSRIs reflects how there is a small pool of antidepressant options and favorable 
profile for safety and greater risk of serotonin syndrome happening (Chan et al. 2015). 






cases related to reactions like serotonin syndrome, also known as serotonin toxicity, are 
commonly observed (Kaye, Kaye, & Volpi 2013). Serotonin syndrome is a group of 
symptoms caused by over-activation of both the peripheral and central postsynaptic 5HT-
1A and 5HT-2A receptors (Kaye, Kaye, & Volpi 2013). Many of the life-threatening 
cases are related to the using of serotonergic drug alone or a combination of different 
drugs with the serotonergic drug (Dunn, Mackay, & Mann 1999).  
Oral fluid (OF) is an interesting alternative biological sample that is on the rise. It 
has characteristic of being non-invasive and easy to collect; so it is suitable to be used in 
the clinical, workplace, driving under influence of drug, drug treatment, and criminal 
justice settings (Bosker & Huestis 2009). OF represents recent-uptake of free analyte 
fraction of the drugs (parent) and its metabolite (Castro et al. 2008). OF is less prone to 
adulteration than urine, and although it has a smaller window of detection time compared 
to urine, the result of on-site OF analysis corresponded closely to urine analysis (Bennett 
et al. 2003). Oral fluid gives similar or better positive rates and higher sensitivity of 
quantification compare to urine in illicit drugs (Borg, Fey, Getto, Kunkel, & Stripp, 
2015). For these reasons, OF seems to be a useful and widely available as an alternative 
matrix for clinical and forensic toxicology analysis; where the tester is interested in 
assessing what’s in the donor’s system at the time of drug test collection. 
The main disadvantages of oral fluid include the reduction and limit of sample 
volume, the required sensitivity of analytical methods to quantify multiple analytes, 
several factors that affect diffusion of analyte from plasma to oral fluid (pH, particle size, 
degree of protein binding, drug pKa and lipophilicity) and the possibility of oral 






draining, suction, or using a commercially available collection device. The collection 
devices offer the advantages of collecting a fixed amount of oral fluid (normally 1 mL) 
and of containing a preservative buffer that limits the instability of the drugs and 
metabolites in the oral fluid. Among the different devices available, Quantisal®  has been 
reported in several applications of OF (Compagnone et al, 2015). 
It is important to quantify antidepressants in the oral fluid because of serious 
clinical and forensic implications, such as therapeutic drug monitoring (TDM) and 
driving under influence (DUI). TDM of antidepressants during the treatment is key for 
the success of it, to optimize the drug therapy experience for the individual patient 
(Bednar et al. 2016) and also for avoiding the risk of any toxicity (Kang & Lee 2009). If a 
patient misses a dose, they are likely to be associated with a discontinuation syndrome. If 
a patient over medicates oneself, then it is likely to be associated with serotonin 
syndrome. If a patient takes additional forms of other drugs, it may lead to serotonin 
syndrome or even death due to drug-drug interactions. For antidepressants, many of the 
overdose result from the combination of drugs such as monoamine oxidase inhibitors 
(MAOI) and SSRI (Gilman 2006). To avoid such situations, it is important to have steady 
state data of prescription drugs in chronic treatment (Ciraulo, Greenblatt, & Shader 
2010).  
Previous studies have shown that there are higher risks of a motor vehicle 
accident with a patient who uses psychotropic drugs because psychoactive drugs may 
impair judgment, thinking, or motor skills (Sansone & Sansone 2009). Antidepressants, 
especially long term SSRIs users, may experience impairment of cognitive and 






performance are affected or potentially interfered by patients having antidepressant 
withdrawal syndrome (Sawyer & Spiller 2007) and the side effects of antidepressants 
(Chihuri et al. 2017).  
Much of the research was done with quantifying antidepressants in blood and 
urine with different methods (Athanaselis et al. 2012; Benites et al. 2013; Fuller et al. 
2013; Berm et al. 2015; Goldstein et al. 2012). A limited number of publications were 
done with detection of multiple antidepressants in oral fluid. Castro et al. (2008) 
presented a fully validated method for analyzing 9 antidepressants in OF using solid 
phase extraction (SPE) and LC-MS/MS while OF was collected by spitting in 
polypropylene tubes. Knihnicki et al. (2014) use micro-extraction by packed sorbent 
(MEPS) and UHPLC-MS to detect 6 antidepressants in OF collected by Salivette®  and 
collected OF were pre-treated by dilution and centrifugation before analysis. Coulter et 
al. (2010) presented a validated method for analyzing 16 antidepressant using LC-
MS/MS in OF by using Quantisal® .  
The aim of this study was to develop a fast procedure for the determination of 18 
antidepressants in oral fluid using SPE and LC-MS/MS analysis. This study could 
contribute to TDM for the characterizing the steady-state concentrations of these 
antidepressants in oral fluid in patients chronically prescribed and DUI involving 
prescription antidepressants. 
 
2. Materials and Methods 






All 18 antidepressants (amitriptyline, bupropion, citalopram, clomipramine, 
cyclobenzaprine, desipramine, desvenlafaxine, doxepin, duloxetine, fluoxetine, 
imipramine, mirtazapine, nortriptyline, paroxetine, sertraline, trazodone, trimipramine, 
venlafaxine) and some of their internal standards (ISTD; amitriptyline-d3, bupropion d9, 
citalopramd6, desipramine d3, doxepin d3, duloxetine d3, fluoxetine d6, imipramine d3, 
nortriptyline d3, venlafaxine d6, paroxetine d6, sertraline d3) were purchased from 
Cerilliant (Round Rock, TX) at 1 mg/mL in methanol. Solvents and chemicals, including 
methanol, dichloromethane, 2-propanol, formic acid, acetic acid, sodium acetate, 
ammonium hydroxide, isopropanol, sodium phosphate, and acetone were purchased from 
VWR International (Bridgeport, NJ). All solvents were high-performance liquid 
chromatography grade or better.  
 
2.2 Oral fluid collection Devices 
Quantisal®  devices for the collection of oral fluid specimens were obtained from 
Immunalysis Corporation (Pomona, CA). The devices contain a collection pad with 
volume adequacy indicator, which turns blue when 1 mL (± 10%) of oral fluid has been 
collected. The pad is placed into a tube containing a buffer (3mL). The total specimen 
volume for the analysis is 4 mL (1 mL oral fluid + 3 mL buffer).  
 
2.3 Oral Fluid Specimens for method development 
Blank oral fluid samples from volunteers obtained by Cordant Health laboratory 
for drug analyses using saliva collection device (Quantisal®  l). Authentic donor oral fluid 






Negative synthetic oral fluid mixed with Quantisal buffer from Immunalysis Corporation 
(Pomona, CA) was used for preparation of calibrators and quality controls. 
 
2.4 Stock solutions 
A 100,000 ng/mL intermediate stock was prepared; firstly, by adding 9 
antidepressants at 1 mg/mL in 10 mL volumetric flask and vortexed for a few seconds. 
Then the mixture was dried completely in 40°C under a stream of nitrogen gas. Repeated 
the same procedure after adding the rest of 9 antidepressants and drying it out. Ten mL of 
methanol was added to the flask and was vortexed for 15 seconds. The solution was 
transferred to the brown bottle labeled Antidepressant Stock 100,000 ng/mL. Other 
intermediate stocks (10,000 ng/mL, 1,000 ng/mL, and 100 ng/mL) containing 18 
antidepressants were made by dilution with methanol. The stock solutions were stored at 
-20°C freezer.   
Three working quality control (QC) standards were prepared in methanol from 
separate stock material at a concentration of 100, 1,000, and 10,000 ng/mL. A deuterated 
internal standard (ISTD) working solution of 10,000 ng/mL was prepared by 
appropriately diluting the ISTD stock solution with 50% methanol in distilled water and 
stored at -20°C freezer until the analysis.  
 
2.5 Calibrators and QCs 
Six calibrators at concentrations of 10, 20, 40, 200, 400, and 1,000 ng/mL and 
three QC samples at concentrations of 40, 200, and 800 ng/mL were prepared by spiking 






drug-free synthetic OF-buffer mixture (0.125 mL OF + 0.375 mL Quantisal buffer) from 
Immunalysis Corporation (Pomona, CA).   
 
2.6 Extraction procedure 
 An automated liquid dispenser (ALD) Cerex®  48, SPEware (Baldwin Park, CA) 
and mixed mode Cerex®  Trace-B cartridges 3mL 35mg, SPEware (Baldwin Park, CA) 
were used in the extraction procedure. To condition the cartridge, 500 µL of methanol 
and then 500 µL of distilled water was added. To activate the cartridge, 1 mL of 0.1M 
sodium phosphate buffer pH 6 was added.  Five hundred µL of the Quantisal®  l sample 
and 30 µL of ISTD at 500 ng/mL were mixed and loaded on to the cartridge. No other pH 
modification was done to samples. Wash was performed with 3 mL of distilled water, 
3mL of 0.1M of acetic acid, and 3mL of 25% methanol in distilled water. Cartridges were 
dried with nitrogen heated to 40°C for 14 minutes. To elute the samples, 750 µL of 
elution solvent (dichloromethane: isopropyl alcohol: ammonium hydroxide; 70:26:4) was 
added to each cartridge. The eluent was evaporated at 40°C under a stream of nitrogen 
gas. The dried extract was reconstituted in 150µL of a mobile phase A, 0.1% formic acid 
in distilled water. The reconstituted sample was transferred to autosampler vials and the 
LC-MS/MS injection volume was 10 µL. 
 
2.7 Instrumental Analysis 
The instrument employed was an Agilent Technologies 6460 LC equipped with 
triple-quadrupole liquid chromatography tandem mass spectrometer (QQQ LC-MS) with 






a direct injection (no column) of 1 µL of each analyte at 1,000 ng/mL. Using the 
molecular weight and the electrospray ion source in the positive mode, the precursor ion 
was obtained and product ion scans at different collision cell energies were performed to 
obtain a list of fragment ions. All tandem mass spectrometer parameters were optimized 
to produce the greatest analyte response. These parameters include source temperature, 
nebulizer gas flow, nebulizer gas pressure, capillary voltage, fragmentor, and collision 
energy. 
The mass spectrometer operated in electrospray positive mode with cell 
accelerator voltage of 7. Scheduled multiple reaction monitoring (MRM) mode was used 
for compound detection with a detection window set of 1 min around the expected 
retention time. The MRM transitions are summarized in Table 1; where two transition 
ions were used for analyte and one transition ion for the internal standard.  
 
 
Table 1. Compound name, precursor ion, product ion, retention time, fragmentor, 











Amitriptyline 278.2 105.1 2.37 45 15 
 
278.2 232.9 2.37 45 13 
Amitriptyline-d3 281.2 105.1 2.37 70 10 
Bupropion 240.1 184 1.65 45 7 
 240.1 131.1 1.65 45 7 
Bupropion-d9 249.2 185.1 1.63 80 10 
Citalopram 325.2 262.2 1.96 15 18 
 
325.2 108.9 1.96 15 18 
Citalopram-d6 331.2 108.8 1.96 50 22 
Clomipramine 315.2 86.1 2.3 50 22 
 
315.2 58.1 2.3 50 22 
Cyclobenzaprine 276.2 231.2 2.33 25 14 






Desipramine 267.3 236.3 2.28 10 6 
 267.2 72.1 2.28 10 6 
Desipramine-d3 270.3 75.1 2.27 10 6 
Doxepin 280.2 235 2.07 110 16 
 280.2 107.4 2.07 110 20 
Doxepin-d3 283.2 107.1 2.07 110 20 
Duloxetine 298.2 154 2.32 80 2 
 
298.2 44.2 2.32 80 16 
Duloxetine-d3 301.1 157.2 2.32 70 2 
Fluoxetine 310.1 148 2.12 70 2 
 
310.1 44.1 2.12 70 2 
Fluoxetine-d6 316.2 154.1 2.11 70 2 
Imipramine 281.2 86.2 2.31 110 12 
 281.2 58.1 2.31 110 48 
Imipramine-d3 284.3 89.1 2.31 90 14 
Mirtazapine 266.2 209.1 1.42 30 16 
 266.2 195.1 1.42 30 16 
Nortriptyline 264.2 233.3 2.34 105 16 
 264.2 117.2 2.34 105 24 
Nortriptyline d3 267.3 117.1 2.34 30 16 
O-desmethylvenlafaxine 264.2 246.2 1.22 100 8 
 
264.2 201.2 1.22 100 8 
Paroxetine 330.2 192 2.28 110 16 
 330.2 70.2 2.28 110 34 
Paroxetine d6 336.2 198.5 2.28 70 10 
Sertraline 307.1 275.8 2.51 85 6 
 307.1 158.8 2.51 85 24 
Sertraline d3 309.1 275.1 2.51 60 4 
Trazodone 372.2 176.1 2 50 14 
 
372.2 148.1 2 50 14 
Trimipramine 295.2 208.1 2.42 50 14 
 295.2 100.2 2.42 50 14 
 295.2 58.1 2.42 50 14 
Venlafaxine 278.2 147.2 1.77 65 18 
 278.2 121 1.77 65 20 
Venlafaxine d6 284.3 266.2 1.76 85 8 
 
Chromatographic optimization was performed by using methods proposed by 
previous publications (Coulter et al 2010, Knihnicki et al 2014, Castro et al, 2008) and 
Cordant Health Solution internal protocol with slight modifications to mobile phase 






(Table 2) using as mobile phase a combination of 0.1% formic acid in distilled water (A) 
and methanol (B) at a flow rate of 0.7 mL/min, column temperature of 50 °C and use of 
Kinetex Biphenyl column (2.1 mm x 50 mm x 2.6 µm). 
 
Table 2. Analytical Pump Time Table with constant flow 
rate of 0.7 mL/min and maximum pressure limit of 1100 
Time (min) A% B% 
0.00 80 20 
1.80 35 65 
2.20 25 75 
2.21 80 20 
 
2.8 Method validation      
  The proposed method was validated by evaluating the linearity, accuracy, 
precision, limit of quantification (LOQ), matrix effect (ME), selectivity, analyte recovery 
(AR), process efficiency (PE), dilution, carry over, auto-sampler stability, and specificity 
based on the Scientific Working Group for Forensic Toxicology (SWGTOX, 2013).  
  Determination of linearity for the calibration curve was investigated over at least 
5 different days using 5 non-zero calibrators. Each calibration curve was prepared using a 
synthetic oral fluid. The calibration curve was evaluated using a least-square residual 
model incorporating different weighting factors (non-weighted, 1/x and 1/x^2) to produce 
an accurate model. Linearity was considered acceptable if the individual residual were 
within a 20% range of the expected concentration, and the coefficient of determinations 
(r^2) was greater than 0.985. The lower limit of quantitation (LLOQ) was chosen to be at 
the same concentration as the lowest non-zero calibrator and were examined in 10 






(LLOQ) samples were required to be within 20% of the expected concentration in order 
to pass.  
Six calibration curve, negative sample, quality control - low (QC-L), quality 
control – medium (QC-M), and quality control – high (QC-H) were extracted on the same 
day and analyzed by LC-MS/MS on five separate days; and expressed by relative mean 
error (RME%), standard deviation (SD%), and coefficient variation (CV%) were 
expressed for intra-day and inter-day precision and accuracy. The precision of this 
method was determined by triplicate analysis of quality control (QC) samples at the 
following concentration: 40, 200, and 800 ng/mL. Samples were analyzed as part of one 
batch to determine intra-day precision of the assay (n=3). Additionally, samples were 
analyzed in triplicate on 5 separate days to determine inter-day precision (n=15). 
 
Accuracy = 100 − (
(expected concentration − calculated concentration)
expected concentration
× 100)  
Intra − day CV% =  
SD of a single run of sample x 100
Mean calculated value of a single run of sample
 
Inter − day CV% =  
SD grand mean of each concentration x 100
Grand mean of each concentration 
 
 
To identify carry over, samples were extracted at the upper limit of linearity, 
ULOL (1,000 ng/mL) and 10 times the concentration of ULOL (10,000 ng/mL). Two 
blank samples were placed after ULOL and three blank samples were placed after 10 X 
ULOL. The detection of the analytes above the limit of detection in blank samples would 






Matrix effect was evaluated comparing the neat, pre-extraction, and post-
extraction response (Chavez-Eng et al. 2003). Negative oral fluid specimens from 15 
donors were selected and analyzed to determine if any significant LC-MS/MS response 
regarding 18 antidepressants was present. Three neat bottles are prepared by adding 1,000 
ng/mL concentration drug panel directly into LC-MS/MS vial to achieve level 6 (400 
ng/mL).  Two sets of 15 real matrices (500 µL) were prepared by spiking with a stock 
solution to achieve 400 ng/ml concentration, level 6.  One set was called pre-extraction 
because drugs were added prior to the extraction. The other set was called post-extraction 
because drugs were added after extraction (directly into the vial). All samples were 
evaporated and followed with reconstitution of 150 µL of 0.1% formic acid in distill 
water. Matrix effect was calculated comparing pre-extraction and neat samples. Analyte 
recovery was calculated comparing post-extraction and pre-extraction samples. Process 
efficiency was calculated comparing post-extraction and neat samples. Matrix effect 
value less than 100% indicate ion suppression and values greater than 100% indicate ion 
enhancement. 
 













To determine if specimens with a higher concentration than the ULOL could be 






1:5, and 1:10 with negative oral fluid (n=4). Results were expected to be within 20% of 
the target value.  
Limit of quantification (LOQ) was defined as the lowest concentration, where the 
analyte could be quantified with a mean relative error less than 20 %. Ten samples were 
spiked at LOQ (level l = 10 ng/mL) in the synthetic oral fluid. 
Selectivity was investigated testing for possible interferences from the specimen 
(endogenous), ISTD, and exogenous factors. To evaluate the interference of endogenous 
factors, 15 authentic donor’s samples, without any presence of analytes of interest or 
ISTD. Interference of endogenous factors was absent if the response at the point of 
interest was below one half of the response of LOD. To evaluate the interference of 
exogenous factors, 10 samples with antidepressant panel spiked at level 1 (10 ng/mL), 
and multiple drug panel (Table 3) spiked at level 7 (1,000 ng/mL) with ISTD in OF 
samples. Interference of exogenous factors was absent if the concentration of the 
antidepressant drugs was within ±20% of 10 ng/mL. To determine if the addition of 
internal standard could contribute to the analyte response, oral fluid specimen from 15 
volunteers were spiked with internal stands and analyzed to determine if any significant 
LC-MS/MS response representing any of the antidepressants. The presence of an LC-
MS/MS peak could indicate possible internal standard impurity. Each drug response and 
ISTD response were compared to see the significance of each. Presence of any peak that 
was not expected would indicate possible impurity. 
Auto-sampler stability was evaluated in extracted samples. Three levels of QCs 






extracted QCs. Any concentration accuracy of over 20% should be considered un-
stability of sample and taken in consideration.  
 
Table3. Interference of exogenous 











































2.9 Authentic and internal control oral fluid specimens  
The method was applied to 7 authentic oral fluid samples previously analyzed by 
Cordant Health Solution Laboratory, by SPE and LC-MSMS. No additional information 
about those cases was available. The samples were collected with Quantisal®  l and stored 
at room temperature until analysis from few days to weeks. The method was also applied 
to 3 samples fortified at the 3 levels (48, 280, 780 ng/mL), as part of an internal 
proficiency test in the laboratory.  
 
Ethics 
Cordant Health Solutions obtained human oral fluid from donation and expired 
ones for the research and development part of the lab. All of the samples were de-
identified and were no longer used in the clinical lab. The research conducted was in an 
acceptable manner, applied towards the planning, execution, and reporting. It was 
performed ethically to protect the interest of the individuals involved and followed all 
federal, professional, and institutional guidelines and regulations. 
 
3. Results 
Calibration curves were linear (1/x^2, weighted regression model) for the 
analytical method, with a correlation coefficient greater than 0.985 over the range from 
10 to 1,000 ng/mL of oral fluid. The ratio of the intensity of the qualifying transitions to 
the intensity of the quantifying transitions was acceptable if the ratio fell within ± 20% 






were within ± 20% ranging from 94-117% as seen in Table 4. Clear separated 













Figure 1. A representative sample chromatogram showing the chromatographic 
separation of all analytes at the LLOQ (10 ng/mL). 
 
Table 4: OF sample spiked at LLOQ (10 ng/mL) accuracy 
 

























For accuracy, percent error of all inter-day analyses was between 0-11.6% and 
intra-day analyses was between 0.7-9.9%. For precision, the relative standard deviation 
of all inter-day analyses was between 3.8-11.3% and intra-day analyses was between 0– 
7.3%. All the accuracy was within 20% and precision was within 15% as shown in Table 
5. The inter-day analysis was based on 5 days and intra-day analysis was one of those 5 
days.  
       Table 5. Intra and Inter-day Precision and Accuracy (Q1: 40 ng/mL, Q2: 200 ng/mL, 
Q3: 800 ng/mL; n=15).  
  Precision (CV%)   Accuracy (% error)  
 Intra-day Inter-day Intra-day Inter-day 
  Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 
Amitriptyline 1.4 0.8 4.1 6.7 5.5 8.9 4.1 3.8 3.7 0.6 0.8 2.9 
Bupropion 0.5 0.2 0.7 4.5 5 7.2 5.2 6.2 5.8 0.5 1 4.4 
Citalopram 2.5 0.9 0.7 5.6 4.7 7.1 2.5 5.6 5.8 1.1 0.2 3.9 
Clomipramine 2.5 1.2 1 6.2 6.7 7.2 1.9 4.9 6.2 1.6 0.1 3.5 
Cyclobenzaprine 4.3 2.4 2.6 7.7 8.5 7.3 8.5 9.3 5 0.2 0 1.8 
Desipramine 1.1 1.6 0.4 6.7 5.8 7.5 2.6 6.2 5.3 1.5 0 4.9 
Doxepin 2.9 2.4 1.2 5.2 7 7.6 5.3 6.9 9.2 1.2 3.2 2.1 
Duloxetine 4.2 2.2 3 8.1 12 5.3 3.3 1.8 5.3 1.9 4.7 5.2 
Fluoxetine 5.6 3.8 0.6 7.6 9.9 8.1 5.3 4.1 5.2 2.5 1.4 5.9 
Imipramine 0.7 1 0 6.9 7.5 7.5 6.1 7.1 7.1 1.5 1.3 3.6 
Mirtazapine 1.5 1.5 0.1 6.7 7 8.2 0.7 5 4.4 1.8 1.7 5.4 
Nortriptyline 3.2 2 2 6.6 5.9 7.7 3.1 4.1 5.6 0.1 0.9 4 
O-
desmethylvenlafaxine 
0.5 1.1 1 6 6.4 9.8 4.1 9.1 7.5 4.9 5.4 2.1 
Paroxetine 6.2 5.4 7.3 5.9 6.4 11.3 9.9 9.1 8.3 11.6 7.9 2.6 
Sertraline 6 0.9 1.4 8 6.8 9.7 4 0.8 7.6 1.7 4 3.9 
Trazodone 1.2 1.1 0.2 3.8 5.6 6.6 1.1 3.9 6 3 0.6 4.5 
Trimipramine 2.6 0.9 4.6 7.3 6.5 4.8 2 5.1 3.3 1.3 0.2 5 
Venlafaxine 2.1 0.3 1 5 4.6 7.6 2.6 6.6 7.7 0.6 2.3 2.7 
 






As shown in Table 6, ME ranged 82.3-114.4%, within ± 20%, shows no 
significant effect; except for bupropion, despiramine, duloxetine, fluoxetine, mirtazapine, 
sertraline, and venlafaxine. The enhancement was observed for bupropion (157%), 
venlafaxine (122%), and mirtazapine (124%). Suppression was observed for duloxetine 
(73.7%), fluoxetine (78%), sertraline (77.7%), and despiramine (76%). CV% of ME were 
between 1.8-13.5%, which is within 15%. All analytical recovery (AR) were ranging 
from 94.6-129%, indicating that the elution solvent (dichloromethane: isopropyl alcohol: 
ammonium hydroxide; 70:26:4) extraction effectively recovers analyte from oral fluid 
samples. All process efficiency (PE) were ranging from 81.5-144.1%.  
 
 Table 6. Matrix Effect (ME), Analyte Recovery (AR), and Process Efficiency (PE) 
(n =15) 
  ME (%) %CV of ME AR (%) PE (%) 
Amitriptyline 111.4 7 94.6 105.4 
Bupropion 157.6 4.5 91.5 144.1 
Citalopram 95.1 9.8 103.1 98 
Clomipramine 86 6.4 104.5 89.9 
Cyclobenzaprine 97.2 3.2 101.3 98.5 
Desipramine 76 8.9 110.9 84.3 
Doxepin 91.1 2.3 100.2 91.3 
Duloxetine 73.7 8.5 129 95 
Fluoxetine 78 4.9 104.4 81.5 
Imipramine 110.5 1.8 100.1 110.6 
Mirtazapine 124.1 3.1 99.1 123 
Nortriptyline 89.5 7.7 105.8 94.7 
O-desmethylvenlafaxine 114.4 8.7 98.3 112.5 
Paroxetine 82.3 3.6 113.9 93.7 
Sertraline 77.7 8 107.1 83.2 
Trazodone 97.9 9.2 99.6 97.5 
Trimipramine 103.7 13.5 99.4 103 
Venlafaxine 122.5 3.9 97.7 119.7 
 
The results of carryover showed no significant carryover, as calculated results for 






will be no or little contamination from the subsequent sample. All diluted samples were 
quantitated within 20% of the expected concentration for all drugs. The quantitative 
values of all analyses in sample 1:2, 1:4, and 1:10 were not influenced by the dilution. 
The stability results showed that 18 antidepressants were stable in room temperature for 
72 h, with accuracy between 88.7-109.8%, within ± 20%. Expect for desipramine at Day 
1 having 65.6% which less than 20%.  
The result of exogenous interference, from ten different source of blank, showed 
average accuracy of 18 antidepressants concentration between 92.5–118.2%; except for 
duloxetine (124%), mirtazapine (123%), paroxetine (129%), and trimipramine (124.6%). 
The results of endogenous interferences from ten different sources of blank oral fluid, 
showed no interfering peaks at either analyte or the ISTD retention time, except 
clomipramine, o-desmethylvenlafaxine, and paroxetine had some increase in drug 
response; however, not significant enough compared to actual drug response. The result 
of ISTD interference from ten different source of blank oral fluid, showed no interfering 
peaks at analyte.  
 
3.5 Authentic OF samples  
The validity of this method was demonstrated by analyzing authentic oral fluid 
from antidepressant users. The authentic oral fluid samples that were already quantified 
in the Cordant Health Solution lab. Ten different antidepressant drugs were detected in 
these seven authentic patient samples (amitriptyline, citalopram, cyclobenzaprine, 
desipramine, fluoxetine, imipramine, nortriptyline, paroxetine, sertraline, and 






previously calculated concentration ranged from 86.3- 111%, as shown in table 7. Also, 
figure 2 shows a chromatogram of some of a positive patient sample. In the internal 
proficiency test samples, the accuracy within ± 20% accuracy ranged from 83.1-112.1% 
as shown in table 8.  
Table 7. Positivity results of patient samples compare to previously quantified 
concentration 
Patient Administered AD Calculated Concentration (ng/mL) Accuracy (%) 
1 Amitriptyline 12.3 86.3 
Nortriptyline 16.8 105.1 
2 Citalopram 160.1 105.5 
3 Cyclobenzaprine 12.5 111 
 Venlafaxine 741.2 104.9 
4 Desipramine 89.5 103.1 
Imipramine 45.4 100.8 
5 Fluoxetine 46.3 103.5 
6 Paroxetine 10.8 107.6 
7 Sertraline 217.7 108.6 
 
Table 8. Positivity Results & accuracy of internal proficiency test samples spiked at 
different concentration 
Spiked AD Calculated Concentration (ng/mL) Accuracy (%) 
Amitriptyline 52.2 108.8 
Bupropion 81.6 112.1 
Citalopram 280.4 101.4 
Clomipramine 271.6 102.9 
Cyclobenzaprine 249.1 88.9 
Desipramine 46.2 96.4 
Doxepin 285.7 102 
Duloxetine 47.8 102.8 
Fluoxetine 290.6 103.8 
Imipramine 47.5 100.8 
Mirtazapine 838.7 107.5 
Nortriptyline 43.6 90.9 
O-desmethylvenlafaxine 42.6 87.5 
Paroxetine 41.8 87.2 
Sertraline 299.9 107.1 
Trazodone 727.9 93.3 
Trimipramine 232.4 83.1 








Figure 2: Chromatogram of positive patient samples: amitriptyline of 13.3 ng/mL, 
sertraline of 217.8 ng/mL, imipramine of 45.4 ng/mL, desipramine of 89.5 ng/mL, 
fluoxetine of 28.2 ng/mL, citalopram of 148.9 ng/mL.  
 
Discussion 
We have developed and validated a method that is specific and sensitive for 
quantification of 18 antidepressants in oral fluid. This study employs 500 µL Quantisal®  
collection device (equals to 125 µL of neat oral fluid) compare to Coulter et al (2010) 
used 1mL from the Quantisal®  collection device (equals to 250 µL of neat oral fluid), 
Knihnicki et al. (2014) used 1 mL of oral fluid from the Salivette swabs, and Castro et al. 
(2008) used 0.2 mL of sample that was spat into polypropylene tubes directly from 
volunteers. Methodology employing a low amount of sample is beneficial if there is a 






Before extraction, Knihnicki et al. (2014) pretreated the oral fluid by adding 0.5 
mL of phosphate buffer (pH 7.4), sonicating for 30 minutes, and centrifuging twice. 
Coulter et al. (2010) added potassium phosphate buffer (0.1M, pH 6) to oral fluid before 
extraction.  Castro et al. (2008) added sodium acetate buffer pH 3.6 to oral fluid before 
the extraction. While for our study, we did not add any additional buffer to the oral fluid 
sample and did not do any pretreatment; which did not affect recovery of analyte 
significantly. This method helped the lab to save the material and the time to handle when 
preparing the oral fluid sample before the extraction. 
For extraction, only the extraction solvent varied compared to previous 
publications. Knihnicki et al. (2014) used 200 µL of methanol, water, and 20% ammonia 
solution (95:4:1, v/v/v), Coulter et al. (2010) used 3 mL of methylene chloride, methanol, 
ammonium hydroxide (78:20:2, v/v/v), and Castro et al. (2008) used 2mL of 
dichloromethane, 2-propanol, ammonium hydroxide (75:24.5:0.5, v/v/v). Similar to 
Castro et al. (2008), 750 µL of dichloromethane, isopropyl alcohol, ammonium 
hydroxide (70:26:4, v/v/v) was used for this research. Following previous studies, 
extraction column was in mixed mode cation exchange and reversed-phase (Coulter et al. 
2010; Castro et al. 2008; Knihnicki et al. 2014). 
We were able to achieve an LLOQ/LOD of 10 ng/mL and linear range of 10-
1,000 ng/mL for oral fluid. Most methods had lower LLOQ and narrower range; Castro et 
al. (2008) used 2-500 ng/mL, Coulter et al. (2010) used 5-500 ng/mL, and Knihnicki et 
al. (2014) used 1.25-10 ng/mL as their linear range. Our LLOQ (10 ng/mL) is higher than 






for the accuracy, making it not suitable for determination of analyte at a lower level. The 
sensitivity of analysis should be improved for the future. 
For the chromatographic separation of analytes, a biphenyl column was used in 
this research compare to C18 column (Castro et al. 2008; Knihnicki et al. 2014; Colulter 
et al. 2010). Mobile phases of 0.1% formic acid in distill water and methanol compare 
was used compared to 0.2% acetic acid and methanol (Colulter et al. 2010) or acetonitrile 
and ammonium formate buffer (Castro et al. 2008) or acetonitrile and diluted phosphoric 
acid (Knihnicki et al. 2014) in previous studies. With the use of biphenyl column giving a 
total run time of 5 min, this study made it faster compare to Castro et al (2008), 8 min 
and Knihnicki et al (2014), in 15 min, but same as Coulter et al (2010), in 5 min. 
For selectivity and especially for exogenous interference, this study analyzed by 
adding 34 different drugs of antipsychotic and other commonly abused drugs. The 
accuracy of duloxetine, mirtazapine, paroxetine, and trimipramine were out of range so 
this should be taken into consideration when analyzing the concentration; since their 
concentration could be higher than expected for future analysis. Coulter et al. (2010) used 
cocaine, benzoylecgonine, cocaethylene, norphetamine, methylenedioxyamphetamine, 
methylenedioxyethylamphetamine, carisoprodol, methadone, diazepam, nordiazepam, 
oxazepam, alprazolam, chlordiazepoxide, bromazepam, temazepam, lorazepam, 
flurazepam, nitrazepam, triazolam, secobarbital, pentobarbital, butalbital, and 
phenobarbital for exogenous interference and no significant interference was observed. 
ME (73.7-157%), AR (94.6-129%), and PE (81.5-144.1%) results for some of the 
drugs were out of the range, but this could be due to no direct isotopically labeled 






Quantisal could have influenced the ME, AR, and PE. Compare to Coulter et al. (2010) 
the recovery of drugs were higher (51.4-87.4%) even with the same use of OF collection 
device, Quantisal. Castro et al. (2008) had a recovery of 49-72%. 
The processed sample stability of oral fluid extracts appears to be stable. No 
significant analyte loss was noticed in any of the QC, suggesting that samples awaiting 
analysis are stable for up to 72 h in room temperature. Castro et al. (2008) analyzed the 
stability of freeze/thaw cycles samples to freshly prepared samples and only sertraline in 
oral fluid showed decrease in the signal. Coulter et al. (2010) analyzed the stability of 




 Based on the validation results, it was demonstrated that this method of SPE and 
LC-MS/MS can be used for reliable identification and quantification of 18 
antidepressants (amitriptyline, bupropion, citalopram, clomipramine, cyclobenzaprine, 
desipramine, o-desmethylvenlafaxine, doxepin, duloxetine, fluoxetine, imipramine, 
mirtazapine, nortriptyline, paroxetine, sertraline, trazodone, trimipramine, and 
venlafaxine) in OF. The major advantage of this method is the rapid run time and 
minimal sample volume with sample preparation. This method could be a useful tool in 
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